Halozyme Therapeu…
USUSDHalozyme Therapeutics Inc (US:HALO) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- halozyme.com
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège social
- San Diego, United States
- PDG
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Employés
- 423
- Fondée
- 1998
- Actions en circulation
- 113.5 M au 2026-07-31
- Flottant
- 112.19 M
- Capitalisation boursière
- 12.53 Md USD
- Initiés
- 1.11%
- Investisseurs institutionnels
- 112.22%
- Secteur d'activité (SIC)
- Biological Products, (No Diagnostic Substances)
- Forme juridique
- XTIQ
- ISIN
- US40637H1095
- LEI
- 529900242I3SV9AGM753
Description
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
Dividendes
Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 11.69% | 13.27 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.71% | 5.35 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.67% | 5.3 M | 2026-06-30 |
| State Street Corporation | 4.56% | 5.18 M | 2026-06-30 |
| iShares Trust-iShares Co… | 3.66% | 4.15 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.32% | 3.76 M | 2026-06-30 |
| Invesco Ltd. | 2.8% | 3.18 M | 2026-06-30 |
| Morgan Stanley | 2.5% | 2.83 M | 2026-06-30 |
| Boston Partners | 2.44% | 2.77 M | 2026-06-30 |
| Bank of America Corporat… | 2.41% | 2.74 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.4% | 2.72 M | 2026-06-30 |
| Geode Capital Management… | 2.22% | 2.52 M | 2026-06-30 |
| William Blair Investment… | 2.21% | 2.51 M | 2026-06-30 |
| John Hancock Funds III-D… | 1.5% | 1.7 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.38% | 1.57 M | 2026-06-30 |
| SPDR SERIES TRUST-State… | 1.31% | 1.49 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.2% | 1.36 M | 2026-06-30 |
| AIM Counselor Series TRT… | 1.1% | 1.25 M | 2026-05-31 |
| First TRT Exch-Trd Fd.-F… | 1.05% | 1.19 M | 2026-08-31 |
| Capitol Series Trust-Ful… | 0.85% | 968 755 | 2026-06-30 |
| TORLEY HELEN I (Chief Ex… | ≈0.68% | 767 780 | 2026-09-11 |
| MATSUI CONNIE L (Directo… | ≈0.16% | 183 035 | 2024-11-29 |
| LABARRE MICHAEL J. (Chie… | ≈0.15% | 173 756 | 2025-02-27 |
| POSARD MATTHEW L (Direct… | ≈0.05% | 58 839 | 2026-09-16 |
| SNYDER MARK HOWARD (Offi… | ≈0.04% | 49 929 | 2026-06-12 |
| CONNAUGHTON BERNADETTE M… | ≈0.04% | 40 418 | 2026-08-10 |
| LABROSSE NICOLE (Chief F… | ≈0.03% | 38 494 | 2026-02-23 |
| HENDERSON JEFFREY WILLIA… | ≈0.03% | 36 572 | 2026-05-05 |
| MIYASHITA AKIKO MONI (Di… | ≈0.02% | 24 937 | 2025-05-01 |
| DUNCAN BARBARA GAYLE (Di… | ≈0.02% | 23 715 | 2026-05-05 |
